Identification of Immune-Related Gene Pair Signature to Predict Prognosis of Diffuse Large B-Cell Lymphoma Based on Bioinformatics Analyses.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2024-09-23 DOI:10.1080/07357907.2024.2405184

Zeinab Davoodi-Moghaddam, Farideh Jafari-Raddani, Davood Bashash

引用次数: 0

Abstract

Since over one-third of DLBCL patients experience relapse or refractory after standard therapy, high-risk patients must be predicted. We developed a prognostic immune-related gene pairs (IRGPs) signature for DLBCL patients using bioinformatics analyses. This signature can predict the prognosis of these patients adequately, either alone or in combination with other clinical parameters. It hopes to improve the stratification and management of these patients for broad clinical applications.

查看原文本刊更多论文

基于生物信息学分析鉴定用于预测弥漫大 B 细胞淋巴瘤预后的免疫相关基因对签名

由于超过三分之一的DLBCL患者在接受标准治疗后复发或难治，因此必须对高危患者进行预测。我们通过生物信息学分析，为DLBCL患者建立了一个预后免疫相关基因对（IRGPs）特征。该特征可以单独或结合其他临床参数充分预测这些患者的预后。它有望改善这些患者的分层和管理，从而广泛应用于临床。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.